Loading...

FITC anti-mouse/rat CD29 Antibody

Pricing & Availability
Clone
HMβ1-1 (See other available formats)
Regulatory Status
RUO
Other Names
integrin β1, VLA-β chain, β1 integrin, GPIIa, ITGB1
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
Hmβ1-1
Lou rat bone marrow cells stained with HMβ1-1 biotin, then detected with Sav-PE
  • Hmβ1-1
    Lou rat bone marrow cells stained with HMβ1-1 biotin, then detected with Sav-PE
  • HMβ1-1_mouse
    Lou rat bone marrow cells stained with HMβ1-1 biotin, then detected with Sav-PE
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
102205 50 µg $101
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102206 500 µg $329
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD29 is a 130 kD protein, also known as integrin β1, VLA-β chain, or GPIIa. It is a member of the integrin family, expressed broadly on leukocytes, endothelial cells, smooth muscle, and epithelial cells. In association with CD49a-f, CD29 forms the VLA-1 through VLA-6 complexes, respectively. It plays an important role in cell-cell or cell-matrix interaction. The HMß1-1 antibody reacts with both mouse and rat CD29. It is able to block cell adhesion and inhibit T cell proliferation.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse, Rat
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Purified mouse VLA-4 (α4β1, CD49d/CD29)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry4 of acetone-fixed frozen sections, in vitro blocking of the adhesion of mouse tumor cell lines to extracellular matrix proteins and in vitro inhibition of T cell proliferative responses1, and in vivo inhibition of neutrophil migration2. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 102235 and 102236).

Application References

(PubMed link indicates BioLegend citation)
  1. Noto K, et al. 1995. Int. Immunol. 7:835.
  2. Ridger VC, et al. 2001. J. Immunol. 166:3484.
  3. Jia W, et al. 2005. Blood 106:3854.PubMed
  4. Economopoulou M, et al. 2005. Blood 106:3831.
  5. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  6. Eisenmann KM, et al. 2007. J. Biol. Chem. doi:10.1074/jbc.M703243200.PubMed
  7. Hayashi Y, et al. 2008. Am J Physiol Gastrointest Liver Physiol. 294:G778. PubMed
  8. Kim DT, et al. 2008. Blood 111:2929.PubMed
  9. Hayashi Y, et al. 2008. J Pharmacol Exp Ther. 326:523. PubMed
  10. Carlson TR, et al. 2008. Development. 135:2193. PubMed
  11. Sangaletti S, et al. 2008. Cancer Res. 68:9050. (Block) PubMed
  12. Baker CM, et al. 2012. PNAS. PubMed.
  13. Hirokawa Y, et al. 2014. Am J Physiol Gastrointerest Liver Physiol. 306:547. PubMed
Product Citations
  1. Chen M, et al. 2021. Bioact Mater. 1.591666667. PubMed
  2. Li L, et al. 2023. Sci Adv. 9:eade1067. PubMed
  3. Guo J, et al. 2023. Cell Rep Med. 4:100881. PubMed
  4. Di Matteo S, et al. 2022. Cancers (Basel). 15: . PubMed
  5. De Schepper S, et al. 2023. Nat Neurosci. 26:406. PubMed
  6. Xin DQ, et al. 2022. Neural Regen Res. 17:2238. PubMed
  7. Volkova MV, et al. 2023. Int J Mol Sci. 24:. PubMed
  8. Xiao Y, et al. 2023. EMBO J. 42:e111762. PubMed
  9. Zhu Y, et al. 2023. Nat Commun. 14:3635. PubMed
  10. Yang M, et al. 2020. Cell Prolif. 53:e12784. PubMed
  11. Stahnke S, et al. 2021. Current Biology. 31(10):2051-2064.e8. PubMed
  12. Zhang Z, et al. 2016. PLoS One. 11: 0162700. PubMed
  13. Contador-Troca M, et al. 2013. Carcinogenesis. 34:2683. PubMed
  14. Rey-Barroso J, et al. 2013. Cell Signal. 25:848. PubMed
  15. Li L, et al. 2017. Stem Cell Research & Therapy . 10.1186/s13287-017-0565-7. PubMed
  16. Dieterich LC, et al. 2019. International Journal of Cancer. 145(10):2804-2815. PubMed
  17. Hu F, et al. 2017. Genomics. 10.1016/j.ygeno.2017.05.004. PubMed
  18. Yang N, et al. 2022. PLoS Negl Trop Dis. 16:e0010175. PubMed
  19. Zou M, et al. 2014. J Biol Chem. 289:17620. PubMed
  20. Pal B, et al. 2017. Nat Commun.. 10.1038/s41467-017-01560-x. PubMed
  21. Zhao J, et al. 2018. Stem Cell Reports. 10:180. PubMed
  22. Takahashi M, et al. 2009. Am J Physiol Heart Circ Physiol. 298:415. PubMed
  23. Lin C, et al. 2022. Nat Commun. 13:6869. PubMed
  24. Sun P, et al. 2021. J Mammary Gland Biol Neoplasia. 26:377. PubMed
  25. Hu Y, et al. 2021. Bioact Mater. 2905:6. PubMed
  26. Chou PR, et al. 2020. Int J Med Sci. 17:354. PubMed
  27. Gu B, et al. 2009. J Cell Biol. 185:811. PubMed
  28. Tong L, et al. 2016. Sci Rep. 6:21642. PubMed
  29. Li CJ, et al. 2018. J Clin Invest. 128:5251. PubMed
  30. Goldstein JM et al. 2019. Cell reports. 27(4):1254-1264 . PubMed
  31. Hou J, et al. 2017. Mol Med Rep. 16:1502. PubMed
  32. Cai W, et al. 2013. J Cell Sci. 126:2877. PubMed
  33. Watzlawik J, et al. 2010. Glia. 58:1782. PubMed
  34. McNeil M, et al. 2021. J Mammary Gland Biol Neoplasia. 26:357. PubMed
  35. Manupati K, et al. 2022. Cancers (Basel). 14:. PubMed
  36. Xu X, et al. 2022. EMBO Rep. 23:e53509. PubMed
  37. Yang Y, et al. 2021. Cell Reports. 34(10):108822. PubMed
  38. Yu JM, et al. 2019. Nat Commun. 4.388888889. PubMed
  39. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  40. Liu F, et al. 2021. Cell Reports. 35(10):109225. PubMed
  41. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  42. Felce JH, et al. 2018. Sci Signal. 11:eaat0756. PubMed
  43. Ge Q, et al. 2018. Mol Med Rep. 17:1667. PubMed
  44. Luo L, et al. 2018. Int J Mol Med. 41:51. PubMed
  45. Guo J, et al. 2018. Int J Mol Med. 41:1976. PubMed
  46. Zhao W, et al. 2022. Bioeng Transl Med. 7:e10303. PubMed
  47. Pal B, et al. 2021. Breast Cancer Res. 23:69. PubMed
  48. Chen K, et al. 2009. Proc Natl Acad Sci U S A. 106:17413. PubMed
  49. Hu J, et al. 2022. Stem Cell Res Ther. 13:349. PubMed
  50. Liu C, et al. 2022. Nat Commun. 13:1989. PubMed
  51. Swanson WB, et al. 2021. Biomaterials. 272:120769. PubMed
  52. Zhu Q, et al. 2021. J Am Heart Assoc. 10:e023491. PubMed
  53. Sribenja S, et al. 2021. Am J Cancer Res. 11:3263. PubMed
RRID
AB_312882 (BioLegend Cat. No. 102205)
AB_312882 (BioLegend Cat. No. 102206)

Antigen Details

Structure
Integrin family, 130 kD
Distribution

Leukocytes, endothelial cells, smooth muscle, epithelial cells

Function
Adhesion
Ligand/Receptor
Extracellular matrix
Cell Type
Embryonic Stem Cells, Endothelial cells, Epithelial cells, Leukocytes, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Immunology, Innate Immunity, Stem Cells
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Noto K, et al. 1995. Int. Immunol. 7:835.
2. Springer TA. 1990. Nature 346:425.

Gene ID
16412 View all products for this Gene ID 24511 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD29
Specificity Alt (DOES NOT SHOW ON TDS):
CD29
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD29 on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account